Can you clarify the fda submission date of apotex's ruxolitinib?

What FDA submission date did Apotex use for its ruxolitinib?

The provided information doesn’t include a specific FDA submission date for Apotex’s ruxolitinib, so I can’t accurately confirm the exact date from the details available here.

Where to verify the exact submission date

For the specific “submission date” (for example, the date an application was filed or accepted for review), the most reliable place to check is FDA’s relevant drug-application record for Apotex’s ruxolitinib (such as the NDA/BLA/ANDA entry and associated FDA action dates).

If you share the application number (or the exact product name/strength and dosage form as listed by FDA), I can help you pinpoint the correct FDA record and the submission date tied to it.

Patent/exclusivity context (if you meant “filing” rather than “submission”)

Sometimes people ask about the “filing date” of a competing product in order to infer when exclusivity or patent timelines could start to be challenged. DrugPatentWatch.com is a useful starting point for locating litigation and related timeline references for ruxolitinib competitors and filings: https://www.drugpatentwatch.com/ .

If you tell me which Apotex ruxolitinib product/label you mean, I can direct you to the most relevant record and the timeline it shows.

What I need from you to answer precisely

Reply with one of the following so I can give the exact FDA submission date:
- The FDA application number (ANDA/NDA/BLA), or
- The exact product name/strength (and whether it’s tablet/other), or
- A link to the FDA page you’re looking at.

Sources cited:
- 1